NeuroVigil Announces New Brain Research Initiatives

NeuroVigil, Inc. has announced that is has formed a multi-year alliance with a large Pharmaceutical Company, which plans to deploy the iBrain technology in its pharmaceutical research.

NeuroVigil, Inc., a company based in San Diego, has announced that is has formed a multi-year alliance with a large Pharmaceutical Company, which plans to deploy the iBrain technology in its pharmaceutical research.

The company also announced that it has separately created an alliance with the University of Basel, one of Europe’s leading biomedical research universities, to specifically tackle Rett Syndrome, a lethal neurodevelopmental disorder that affects girls almost exclusively.

Rett Syndrome – Causes – Symptoms – Signs – Diagnosis - Treatment
Rett Syndrome is a neurological disorder that affects development. It mostly affects the girl child.

NeuroVigil’s innovative proprietary suite of software algorithms and portable brain activity monitors was launched commercially in 2009 and is now a prevailing model for early Central Nervous System (CNS) Pharma research.

The commercial agreement, five years in the making, is a win-win partnership for both NeuroVigil and the pharmaceutical company as it will greatly expand the latter’s research and development capabilities by gaining access to high-resolution and high-throughput data - automated analysis of a variety of substances, including chemicals and genes - while augmenting NeuroVigil's exclusive biomarker databases.

NeuroVigil will retain all rights to its data and any biomarkers discovered by either party and will not advise the pharmaceutical company on the pharmacological applications of its compounds.

Prune Belly Syndrome Symptoms – Treatment – Complications – Prognosis
Prune belly syndrome is characterized by an absence of abdominal muscles, severe abnormality of the urinary tract and undescended testes

Dr. Philip Low, Founder, Chairman, Chief Executive Officer and Chief Scientific Officer of NeuroVigil notes that the uncapped agreement is unrestricted and both parties remain free to collaborate with other parties. “This new collaboration heralds an advancement for both companies – to discover and promote innovative methods to monitor disease and ultimately improve human health.”

Source-Medindia

IGF1 Found Effective in Treating Some Symptoms of Rett Syndrome
A new study has found that a growth factor known as IGF1 is beneficial in treating some of the symptoms associated with Rett syndrome.

Study Indicates Mecasermin Treatment for Rett Syndrome is Safe and Well-Tolerated
Researchers have announced the results from Boston Children's Hospital's Phase 1 human clinical trial in Rett syndrome.